Conference on Retrovirus and Opportunistic Infections (CROI 2020)

08 March 2020 - 11 March 2020

CAC progression up in men with HIV on testosterone therapy

10 Jun 2020 by

Men with HIV who are on testosterone therapy appear to have an elevated risk for significant coronary artery calcium progression (CAC) vs those who are not on it, according to a study released at CROI 20.

CAC progression up in men with HIV on testosterone therapy

10 Jun 2020

Does a single round of 3HP work for PLWH on ART?

28 May 2020 by

A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.

Does a single round of 3HP work for PLWH on ART?

28 May 2020

DTG/FTC/TAF a suitable ART regimen in pregnancy

14 May 2020 by

The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.

DTG/FTC/TAF a suitable ART regimen in pregnancy

14 May 2020

Second patient cured of HIV through stem cell transplant

13 May 2020 by

The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.

Second patient cured of HIV through stem cell transplant

13 May 2020

Overall, not comorbidity-free, life expectancy gap narrowed between HIV+, HIV- persons

24 Apr 2020 by

The gap in overall life expectancy between people with HIV (PWH) and those without HIV has narrowed over time, particularly among optimally treated PWH. However, PWH still have fewer comorbidity-free years than those without HIV, according to a study presented at CROI 2020.

Overall, not comorbidity-free, life expectancy gap narrowed between HIV+, HIV- persons

24 Apr 2020

Short-course sofosbuvir-velpatasvir inferior to standard course for HCV

16 Apr 2020 by

A six-week course of sofosbuvir-velpatasvir is insufficient to achieve virological response among patients with recent hepatitis C virus (HCV) infection, according to the phase IV REACT* trial.

Short-course sofosbuvir-velpatasvir inferior to standard course for HCV

16 Apr 2020

Bone mass higher in HIV+ children on efavirenz than lopinavir/ritonavir

13 Apr 2020 by

Children with HIV (HIV+) who switched to efavirenz had higher bone mass even after 4 years of switching compared with those who remained on an antiretroviral therapy (ART) regimen comprising lopinavir and ritonavir, according to data presented at CROI 2020.

Bone mass higher in HIV+ children on efavirenz than lopinavir/ritonavir

13 Apr 2020

TB prevalence high in MDR-TB household contacts

08 Apr 2020 by

A high number of household contacts (HHCs) of adults with multi-drug-resistant tuberculosis (MDR-TB) will develop the infection, according to the PHOENIx Feasibility study presented at CROI 2020.

TB prevalence high in MDR-TB household contacts

08 Apr 2020

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

01 Apr 2020 by

A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine shows therapeutic potential over an oral antiretroviral therapy (ART) regimen in adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

01 Apr 2020

Every-2-month cabotegravir + rilpivirine feasible for HIV treatment

27 Mar 2020 by

Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.

Every-2-month cabotegravir + rilpivirine feasible for HIV treatment

27 Mar 2020